Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287108 | 1.00 | CYP3A4 (0.45) | CYP3A4MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL801584 | 0.85 | DTYMK (0.46) | MAPTALDH1A1KMT2ALMNAVCAM1 | |
| SCHEMBL30287096 | 0.83 | CA12 (0.43) | CYP3A4MAPTKMT2ALMNAVCAM1 | |
| SCHEMBL2185789 | 0.83 | CA12 (0.43) | CYP3A4MAPTKMT2ALMNAVCAM1 | |
| SCHEMBL8564329 | 0.81 | ALDH1A1 (0.50) | CYP3A4MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL29105409 | 0.80 | RAB9A (0.40) | MAPTALDH1A1KMT2ALMNANPC1 | |
| Nitrous Acid SCHEMBL29105411 | 0.80 | DTYMK (0.45) | MAPTALDH1A1KMT2APOLB | |
| SCHEMBL29828356 | 0.80 | POLB (0.47) | MAPTALDH1A1KMT2ALMNASIRT6 | |
| SCHEMBL1092975 | 0.80 | POLB (0.47) | MAPTALDH1A1KMT2ALMNASIRT6 | |
| SCHEMBL27824182 | 0.80 | POLB (0.36) | MAPTALDH1A1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650909-B | Synthesis method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-115650909-A | Synthetic method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4587124-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | Enliven Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| CN-115650909-B | Synthesis method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-115650909-B | Synthesis method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024059558-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-116568689-A | Polycyclic pyrimidine derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023067546-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-04-27 | — | — | WO | disclosed |
| CN-115650909-A | Synthetic method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2015200534-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200534-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-2366691-B1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO LTD (CN) | 2015-04-15 | — | — | EP | disclosed |
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | disclosed |
| EP-2366691-A1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | Beijing Yiling Bioengineering Co., Ltd. (CN) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | CYP3A4 90/4885MAPT 3373/4885BLM 2669/4885 |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | KRAS, NRAS, SOS1 | CYP3A4 1942/4885MAPT 4329/4885BLM 2708/4885 |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | CYP3A4 90/4885MAPT 3373/4885BLM 2669/4885 |
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ERBB2, BRCA1, ERBB3 | CYP3A4 2124/4885MAPT 4421/4885BLM 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.